Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TPMT | P51580 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.38 |
| ▸ | RXRB | P28702 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.36 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6397570 | 1.00 | LMNA (0.50) | LMNAMAPK1TPMTBLMNPSR1 | |
| SCHEMBL1573368 | 1.00 | LMNA (0.50) | LMNAMAPK1TPMTBLMNPSR1 | |
| SCHEMBL13238635 | 0.86 | LMNA (0.42) | LMNAMAPK1TPMTBLMNPSR1 | |
| SCHEMBL13979380 | 0.86 | LMNA (0.42) | LMNAMAPK1TPMTBLMNPSR1 | |
| SCHEMBL12588339 | 0.86 | LMNA (0.42) | LMNAMAPK1TPMTBLMNPSR1 | |
| SCHEMBL23973511 | 0.81 | TAS2R14 (0.40) | LMNAMAPK1RXRARXRBAKR1C3 | |
| SCHEMBL1573058 | 0.79 | LMNA (0.48) | LMNAMAPK1BLMNPSR1TSHR | |
| SCHEMBL1573057 | 0.79 | LMNA (0.48) | LMNAMAPK1BLMNPSR1TSHR | |
| SCHEMBL31407019 | 0.79 | LMNA (0.59) | LMNAMAPK1BLMNPSR1TSHR | |
| SCHEMBL2164471 | 0.79 | LMNA (0.59) | LMNAMAPK1BLMNPSR1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090478-A1 | Platinum complexes and their use in cancer treatment | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE (IL) | 2005-04-28 | — | — | US | claimed |
| US-8044067-B2 | Isoquinolines as IGF-1R inhibitors | ANALYTECON S.A. (CH) | 2011-10-25 | — | — | US | disclosed |
| EP-1931636-B1 | ISOQUINOLINES AS IGF-1R INHIBITORS | ANALYTECON SA (CH) | 2011-04-13 | — | — | EP | disclosed |
| US-6921758-B2 | Amino acid derivatives | ASTRAZENECA AB (SE) | 2005-07-26 | — | — | US | disclosed |
| US-20040087647-A1 | NEW AMINO ACID DERIVATIVES | ASTRAZENECA AB | 2004-05-06 | — | — | US | disclosed |
| US-6617320-B2 | Protease inhibitor; anticoagulants | ASTRAZENECA AB (SE) | 2003-09-09 | — | — | US | disclosed |
| EP-0836615-B1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | ASTRAZENECA AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| US-20020042396-A1 | Amino acid derivatives | ASTRA AB | 2002-04-11 | — | — | US | disclosed |
| US-6337343-B1 | TREATMENT OF THROMBOSIS WITH ANTICOAGULANTS | ASTRAZENECA AB (SE) | 2002-01-08 | — | — | US | disclosed |
| US-6051568-A | Thrombin inhibitors, their preparation and use | ASTRA AKTIEBOLAG (SE) | 2000-04-18 | — | — | US | disclosed |
| EP-0836615-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | Astra Aktiebolag (SE) | 1998-04-22 | — | — | EP | disclosed |
| WO-1997002284-A1 | NEW THROMBIN INHIBITORS, THEIR PREPARATION AND USE | ASTRA AKTIEBOLAG (SE) | 1997-01-23 | — | — | WO | disclosed |
| US-4218380-A | OXIDATION OF THE A-HYDROXY-ARYLACETIC ACID | BAYER AKTIENGESELLSCHAFT (DE) | 1980-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090478-A1 | Platinum complexes and their use in cancer treatment | PAICS, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, PIN1 | LMNA 3495/4885MAPK1 4630/4885TPMT 1439/4885 |
| US-20020042396-A1 | Amino acid derivatives | F2, SERPINC1, ARGLU1 | LMNA 3361/4885MAPK1 1223/4885TPMT 1812/4885 |
| US-20040087647-A1 | NEW AMINO ACID DERIVATIVES | F2, ANPEP, PEPD | LMNA 2654/4885MAPK1 1138/4885TPMT 2142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.